Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 2,720.00 | |
50 mg | 10-14 weeks | $ 3,580.00 | |
100 mg | 10-14 weeks | $ 4,900.00 |
Description | CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM. |
Targets&IC50 | CDK1:110 nM (ki), CDK4:0.3 nM (ki), CDK6:2.2 nM (ki) |
In vitro | CDK4/6-IN-3 inhibits MCF7 and BT549 cell lines proliferation (EC50s: 30 nM and 2.1 μM). |
Molecular Weight | 462.57 |
Formula | C25H31FN8 |
CAS No. | 2366237-37-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CDK4/6-IN-3 2366237-37-6 Cell Cycle/Checkpoint CDK CDK4/6 IN 3 CDK-4/6-IN-3 CDK4/6IN3 inhibitor inhibit